Amgen

Open: 263.3 Close: 265.12 Change: 1.83

How to know if Amgen Stock is a risky investment without reading the whole internet.

Are looking for the most relevant information about Amgen? Investor spend a lot of time searching for information to make investment decisions in Amgen. This task is often burdensome and consumes huge amounts of free time. It also leads to mistakes due to fatigue and bounded rationality. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Amgen are: Amgen, share, Inc, earnings, year, raise, Amgens, and the most common words in the summary are: amgen, news, stock, amgens, earnings, amgn, report, . One of the sentences in the summary was: Truist Securities analyst Robyn Karnauskas upgrades Amgen from Hold to Buy.. Other searches related …

Concept Map

Semantic Network

Stock Summary

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's products include Enbrel, Prolia, Xgeva, Otezla, Aranesp, and Repatha..

Today's Summary

Amgen Inc. will host a webcasted call for the investment community at 8:00 a.m. on November 19. Amgen expects full-year earnings in the range of $18.20-$18.80 per share. Truist Securities analyst Robyn Karnauskas upgrades Amgen from Hold to Buy.

Today's News

Amgen Inc. per Employee $1.057M P/E ratio 18.85M P /E Ratio 18.06 Yield 3.21% Dividend $2.13 Ex-Dividend date Nov 16, 2023. Amgen expects full-year earnings in the range of $18.20 to $18.80 per share. Amgen shares have risen slightly since the beginning of the year. Amgen Inc. (AMGN) stock price, quote & news - stock analysis. Amgen has supported Cal State East Bay for several years via the Amgen Foundation and increased their support this year. The biotech blew past earnings estimates for the third quarter and again raised its guidance. Amgen Inc. (NASDAQ:AMGN) will host a webcasted call for the investment community at 8:00 a.m. on November 19. Amgen is a leader in biotechnology-based human therapeutics. Amgen completes $27.8 billion Horizon Therapeutics deal. Mirati (MRTX) Surges 45% as Sanofi Reportedly Eyes Buyout. Amgen expects full-year earnings in the range of $18.20-$18.80 per share. Truist Securities upgraded outlook for Amgen from Hold to Buy on November 2, 2023. RBC raises price target on Amgen to $256 from $253, keeps sector perform rating. Truist Securities analyst Robyn Karnauskas upgrades Amgen from Hold to Buy. Seigerman notes that while Amgens base business was able to exceed consensus expectations for 3Q23, the companies new product launches, particularly Lumakras, significantly underperformed. Amgen announced new Phase 3 CodeBreaK 300 results for its KRASG12C inhibitor combination in patients with metastatic colorectal cancer (mCRC) Amgens Otezla And BMSs Sotyktu battle for share in Oral Psoriasis drug market. Baxaltas Antibody Patent Held Invalid under Amgens Enablement Standard by the Federal Circuit. Amgen is an Equal Opportunity Employer. Amgen announces presentation of new scientific and clinical research across its expanded rheumatology pipeline. Amgen sales rise, but shares off as investors await obesity data. Full-year sales forecast raise only reflected additional revenue from its $27.8 billion acquisition of Horizon Therapeutics.

Stock Profile

"Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California."

Keywords

The game is changing. There is a new strategy to evaluate Amgen fundamental value, possible risks and most salient advantages. Investors have traditionally relied in reading large amounts of text to evaluate the fundamental value of a stock or company. However, the development of Artificial Intelligence (AI) tools is modifying the way investments are evaluated in markets. Today, machine learning, natural language processing and bigdata allow making this process automatic, reducing large amounts of text to the elements that have a higher activation in a neural network. We programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Amgen are: Amgen, share, Inc, earnings, year, raise, Amgens, and the most common words in the summary are: amgen, news, stock, amgens, earnings, amgn, report, . One of the sentences in the summary was: Truist Securities analyst Robyn Karnauskas upgrades Amgen from Hold to Buy.. Other searches related to this term that the AI found were: stockmarketlive, livestock, stockmarketforbeginners, thestockmarket, stockmarkettoday, stockmarkettrading, stockmarketstocks, todaystockmarket, thestockmarket, marketnews, stockmarketnews, whatisstockmarket, usstockmarket, stockmarketopen. #amgen #news #stock #amgens #earnings #amgn #report.